Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
LucasBio is a synthetic biology company that integrates artificial intelligence, protein engineering, and high-throughput automation to develop next-generation bio-based products. The company's platform focuses on the de novo design of enzymes and proteins to enable efficient production of pharmaceutical intermediates, nutritional ingredients, and specialty chemicals. LucasBio aims to transform traditional manufacturing by providing sustainable, cost-effective biological alternatives to chemical synthesis. Their technology stack includes proprietary AI algorithms for protein structure prediction and a fully automated laboratory for rapid experimental validation. By optimizing biocatalytic processes, the company helps pharmaceutical partners reduce costs and environmental impact in drug production.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on LucasBio.